Wall Street brokerages predict that AC Immune SA (NASDAQ:ACIU) will announce earnings of ($0.22) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for AC Immune’s earnings, with estimates ranging from ($0.25) to ($0.20). AC Immune posted earnings of ($0.20) per share in the same quarter last year, which would suggest a negative year over year growth rate of 10%. The business is scheduled to issue its next quarterly earnings report on Thursday, March 19th.
On average, analysts expect that AC Immune will report full-year earnings of $0.70 per share for the current financial year, with EPS estimates ranging from $0.69 to $0.71. For the next financial year, analysts anticipate that the business will post earnings of ($0.77) per share, with EPS estimates ranging from ($0.88) to ($0.71). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover AC Immune.
AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Wednesday, November 13th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.08. AC Immune had a return on equity of 19.18% and a net margin of 45.19%. The company had revenue of $33.90 million during the quarter, compared to the consensus estimate of $31.50 million.
Several research firms recently issued reports on ACIU. HC Wainwright reiterated a “buy” rating and set a $11.00 target price (up previously from $8.00) on shares of AC Immune in a report on Tuesday, December 10th. Zacks Investment Research lowered shares of AC Immune from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. BidaskClub lowered shares of AC Immune from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. TheStreet upgraded shares of AC Immune from a “d” rating to a “c” rating in a research note on Monday, November 18th. Finally, ValuEngine downgraded shares of AC Immune from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. AC Immune has an average rating of “Hold” and a consensus target price of $10.83.
A number of large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its position in shares of AC Immune by 12.6% in the second quarter. Renaissance Technologies LLC now owns 248,039 shares of the company’s stock valued at $1,377,000 after purchasing an additional 27,789 shares during the period. Citadel Advisors LLC raised its holdings in AC Immune by 34.2% in the 2nd quarter. Citadel Advisors LLC now owns 166,427 shares of the company’s stock valued at $924,000 after acquiring an additional 42,414 shares during the period. Millennium Management LLC raised its holdings in AC Immune by 516.5% in the 3rd quarter. Millennium Management LLC now owns 122,806 shares of the company’s stock valued at $607,000 after acquiring an additional 102,887 shares during the period. Acadian Asset Management LLC acquired a new stake in AC Immune during the second quarter worth approximately $492,000. Finally, Athanor Capital LP acquired a new stake in AC Immune during the second quarter worth approximately $234,000. Hedge funds and other institutional investors own 27.81% of the company’s stock.
Shares of NASDAQ:ACIU traded down $0.01 during midday trading on Tuesday, reaching $8.19. 5,604 shares of the company were exchanged, compared to its average volume of 139,827. The firm has a market cap of $536.43 million, a PE ratio of -9.99 and a beta of 0.32. The company has a quick ratio of 22.09, a current ratio of 22.08 and a debt-to-equity ratio of 0.01. AC Immune has a fifty-two week low of $3.25 and a fifty-two week high of $12.15. The stock has a fifty day simple moving average of $7.57 and a two-hundred day simple moving average of $5.88.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Further Reading: Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.